Can drug developers and regulators create a sustainable culture that allows the biopharma industry to continue to work with the accelerated model adopted during the COVID-19 pandemic, or will industry burnout ensue?
Programmed by Economist Impact and sponsored by MilliporeSigma The art of the possible: reimagining the biopharmaceutical supply chain will examine what leaders in the biopharmaceutical supply chain must do to steer their businesses through a time of rapid change and ongoing disruption, and identify synergies and efficiencies to bring drugs to market more effectively.
Life Science MilliporeSigma
Head of Strategy, Business Development and Sustainability
Vice President, Supply Chain
Anne McDonald Pritchett
Senior Vice President, Policy and Research
Senior Manager, Health, Policy and Insights
Pharma and biopharma manufacturing
Session 1:presented October 4, 2022
To continue reading please sign in or create an account.Don't Have An Account?